COMP <GO>
IBRX vs ABBV // 10Y YIELD & FRED MACRO BETA
ImmunityBio Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: IBRX 4
— ABBV 10
▲ 10Y YIELD & FRED MACRO BETA LEADER: ABBV
LAST: $8.29 (-5.15%) • MKT CAP: $9.26B
macro-sensitivity
1.05
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
macro-sensitivity
1.15
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IBRX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IBRX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | IBRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -27.30% | 29.00% | -56.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.33% | 3.47% | -6.80 | ABBV | /fcf-yield <GO> |
| Operating Margin | -60.00% | 24.60% | -84.60 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 6.90% | -66.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 8.60% | +171.40 | IBRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.33 | -4.88 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | IBRX | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 72.8 | -28.97 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 1.05 | 1.15 | -0.10 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.0x | 113.1x | -84.10 | IBRX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.26B | $513.86B | -$504.60B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IBRX REV | ABBV REV | IBRX GROSS % | ABBV GROSS % | IBRX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $113.3M | $61.16B | 99.3% | 70.2% | -$308.8M | $17.82B |
| FY 2024 | $14.7M | $56.33B | 100.0% | 70.0% | -$398.1M | $17.83B |
| FY 2023 | $622.0K | $54.32B | 44.0% | 44.0% | -$366.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IBRX // BETA 1.05
ABBV // BETA 1.15